Results 271 to 280 of about 67,878 (296)

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Nature, 2014
Eric S Fischer, Michael B Stadler, Simone Cavadini   +2 more
exaly  

Identification of a Primary Target of Thalidomide Teratogenicity

Science, 2010
Takumi Ito, Yuki Yamaguchi, Hiroshi Handa   +2 more
exaly  

Thalidomide

Cancer Practice, 2000
openaire   +2 more sources

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Lancet, The, 2019
Phillipe Moreau, Michel M Attal, `Cyrille Hulin   +2 more
exaly  

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN

Science, 2018
Quinlan Lloyd Sievers, Georg Petzold, Richard D Bunker   +2 more
exaly  

Thalidomide

Reactions Weekly, 2009
openaire   +1 more source

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Lancet, The, 2007
Thierry Facon, Michel M Attal, Ibrahim Yakoub Agha   +2 more
exaly  

Thalidomide

Reactions Weekly, 2021
openaire   +1 more source

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

Lancet, The, 2006
Antonio Palumbo, Sara Bringhen, Valerio De Stefano   +2 more
exaly  

Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group

Journal of Clinical Oncology, 2006
S Vincent Rajkumar, Rafael Fonseca
exaly